11th week of 2011 patent applcation highlights part 35 |
Patent application number | Title | Published |
20110064673 | New L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them - The present invention relates to fluorinated glutamic acid (glutamate) and glutamine derivatives wherein the fluorine atom is 19F. The glutamic acid (glutamate) and glutamine derivatives are compound(s) of general Formula I, which encompasses all possible diastereoisomers and/or enantiomere derivatives or mixtures thereof. | 2011-03-17 |
20110064674 | LUMINESCENT MULTIMODAL NANOPARTICLE PROBE SYSTEM AND METHOD OF MANUFACTURE THEREOF - A method of manufacture of a luminescent nanoparticle probe system includes forming a bismuth sulfide core; and coating the bismuth sulfide core with a shell. | 2011-03-17 |
20110064675 | ELEMENTAL IRON NANOPARTICLES - Synthesis of iron nanoparticles with a substantially unoxidized iron core and a biocompatible coating is described. The nanoparticles are formed by reacting an iron salt solution with a reducing agent in a substantially oxygen-free environment and exposing the formed iron particles to a biocompatible coating agent in a substantially oxygen-free environment to form coated iron particles. An average diameter of the coated iron particles is between 5 nm and 25 nm. The biocompatible coating can functionalized with cell-specific agents for use as diagnostic and therapeutic agents. | 2011-03-17 |
20110064676 | Diagnostic and therapeutic nanoparticles - The present invention relates to diagnostic and therapeutic nanoparticles. More particularly, the present invention relates to creating a hybrid gold/gold sulfide nanoparticle with a chitosan matrix surrounding the metallic nanoparticle and a method for making the same. The chitosan-coated gold/gold sulfide nanoparticles can then be incorporated with additional therapeutic or diagnostic compounds such as iodine, antibodies, or other suitable compounds. The nanoparticles of the present invention have the dual capabilities of absorbing near infrared wavelength light to (1) act as a therapeutic agent by generating heat energy effective for cell ablation or for release of therapeutic compounds embedded in the chitosan matrix and (2) creating diagnostic benefit by incorporation of X-ray or MRI contrast-agents. | 2011-03-17 |
20110064677 | LIPOXIN ANALOGS AND METHODS FOR THE TREATMENT OF PERIODONTAL DISEASE - This invention provides new lipoxin analogs, compositions containing analogs, and methods of using these compounds and compositions for treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease. The invention also provides for methods of treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease with compositions containing COX-2 inhibitors. Further, the invention provides methods for preventing systemic diseases beyond theoral cavity that are related to periodontal disease using the composition containing lipoxin analogs, COX-2 inhibitors, or both. | 2011-03-17 |
20110064678 | STYLING AGENTS GIVING A HIGH DEGREE OF HOLD - An agent for the temporary deformation of keratinic fibers comprises, in a cosmetically acceptable carrier, a) at least one copolymer A formed from: at least one monomer A1 selected from acrylic acid, methacrylic acid, acrylic acid alkyl esters, and methacrylic acid alkyl esters; at least one monomer A2 selected from acrylic acid hydroxyalkyl esters and methacrylic acid hydroxyalkyl esters; and at least one monomer A3 selected from succinic acid monoalkyl esters and succinic acid dialkyl esters; and at least one film-forming and setting amphoteric polymer. A method for using the agent for the temporary deformation of hair, and an aerosol hair spray containing the agent and at least one propellant also are provided. | 2011-03-17 |
20110064679 | OXALOACETIC ACID AND SALTS OF OXALOACETIC ACID AS A FLAVOR, AN ACIDIZING AND A PRESERVATIVE AGENTS AND METHODS FOR PREPARING AND USING SAME - Provided herein is a method for flavoring an ingestible composition with an organoleptically effective amount of the flavoring agent. The flavoring agent may be used in a wide variety of ingestible vehicles such as chewing gum compositions, hard and soft confections, toothpaste, dairy products, beverage products including juice drinks and juice products, green vegetable and chicken products, salad dressings, deserts, bottled water, frozen treats and the like. The present invention also pertains to an ingestible composition comprising an ingestible vehicle and an organoleptically effective amount of the purified flavoring agent. The present invention also pertains to oxaloacetic acid and salts of oxaloacetic acid, represented by the formula, HOOCCH2CO—COOH and salts of the same. The invention further uses oxaloacetic acid and salts of oxaloacetic acid as a method to preservative in the preparation of ingestible compositions, without increase in toxicity. The invention further uses oxaloacetic acid as a ingestible acidizer, without increase in toxicity. | 2011-03-17 |
20110064680 | NATURALLY DERIVED WATERPROOFING AGENTS FOR AQUEOUS-BASED PERSONAL CARE PRODUCTS - Personal care compositions such as sunscreens, color make-up, lotions and creams which contain an amount of a hydrogenated rosin or resin which provides increased resistance to removal by water of such personal care compositions. | 2011-03-17 |
20110064681 | POLYURETHANES AS RHEOLOGICAL MODIFYING MEANS FOR COSMETIC PREPARATIONS - The present invention relates to cosmetic preparations comprising novel polyurethanes or mixtures thereof as means for modifying rheological properties. | 2011-03-17 |
20110064682 | COSMETIC COMPOSITION COMPRISING A STEM-CELL CULTURE FLUID, AND A PRODUCTION METHOD THEREFOR - The present invention relates to a method of improving wrinkle, whitening or anti-oxidation of a skin, and more specifically, to a method of improving wrinkle, whitening or anti-oxidation of a skin, comprising applying a cosmetic composition comprising a stem cell culture fluid as an active ingredient to the skin. Further, the present invention provides a method for preparing the cosmetic composition, comprising the steps of culturing stem cells and isolating the stem cells from the culture fluid. | 2011-03-17 |
20110064683 | PERSONAL CARE COMPOSITIONS WITH ETHYLENE ACRYLIC ACID COPOLYMER AQUEOUS DISPERSIONS - Described are personal care compositions, comprising an aqueous dispersion comprising an ethylene acrylic acid copolymer and a least one cosmetically acceptable surfactant, emollient, or cosmetic active. | 2011-03-17 |
20110064684 | Method of chemically modifying the internal region of a hair shaft - A method of chemically modifying the internal region of a hair shaft, comprising the steps of: providing and applying to hair a treatment composition comprising from 0.1% to 20% of an ethylenic monomer by weight of the total composition, an initiator and a dermatologically acceptable carrier; and exposing the hair to a relative humidity of at least 70%, within 1 h of applying the treatment composition, and said exposure lasting for 10 to 90 min. Said method provides improved performance, efficacy and/or efficiency. | 2011-03-17 |
20110064685 | SILICONE REPLACEMENTS FOR PERSONAL CARE COMPOSITIONS - Described are personal care compositions, comprising an aqueous dispersion comprising a metallocene catalyzed polyolefin and an ethylene acrylic acid copolymer; a cationic polymer; and a least one cosmetically acceptable surfactant, emollient, or cosmetic active, provided that the personal care composition contains less than 0.09 wt % of silicone, and preferably is substantially free of silicone. | 2011-03-17 |
20110064686 | CATIONIC POLYMERS AS CONDITIONING AGENTS - The present invention provides personal care compositions comprising a cosmetically acceptable, cationically modified ethylene acrylic acid polymer that has a net cationic charge at pH 6, and a least one cosmetically acceptable surfactant, emollient, or cosmetic active. | 2011-03-17 |
20110064687 | MONO-, DI- AND POLYOL PHOSPHATE ESTERS IN PERSONAL CARE FORMULATIONS - A hydrophilized personal care formulation, which can be in the form of a hand or body soap (liquid or bar), lipstick, body wash, makeup remover, skin cleaner, hair conditioner, skin or hair moisturizer. The formulation employs an organophosphorus material or a mixture of an organophosphorus material, for example, mono-, di-, and polyol phosphate esters. | 2011-03-17 |
20110064688 | SILICONE DEPOSITION AID FOR PERSONAL CARE COMPOSITIONS - Described are personal care compositions, comprising an aqueous dispersion comprising silicone and an ethylene acrylic acid copolymer; and at least one cosmetically acceptable surfactant, emollient, or cosmetic active. | 2011-03-17 |
20110064689 | IN SITU IMMUNIZATION - The arming of activated T cells (ATC) with BiAbs can overcome major barriers for successful adoptive immunotherapy. The BiAb approach takes the advantage of the targeting specificity of monoclonal antibodies and the cytotoxic capacity of T cells to lyse tumors. Arming of ATC with BiAb makes every T cell an antigen-specific CTL and infusions of such cells will markedly increase the effective precursor frequency of CTL in the cancer patient. Furthermore, the ability of such armed ATC to kill multiple times without rearming with BiAb, secrete tumoricidal cytokines, secrete chemokines, and survive in patients for up to 8 days after the last infusion or in Beige/SCID mice for over 13 weeks after cessation of treatment. The persistence of cells in the Beige/SCID after infusion show long-term survival capability in the host. Re-stimulation of armed ATC after 3 cycles of cytotoxicity with tumor cells resulted in the secretion of interferon gamma indicating the development of tumor specific immune responses in the population of cells that have been exposed multiple times to antigen. In summary, armed ATC can act as a cytotoxic “drug”, kill multiple times (direct killing), divide after killing (increasing the effector:target ratio in vivo), secrete tumoricidal cytokines (indirectly killing), secrete chemokines at the tumor site (recruit naive T cells and antigen-presenting cells to immunize the patient to tumor lysate) and persist in patients and animal models for weeks to months (long-term survival). | 2011-03-17 |
20110064690 | Pegylated Interleukin-10 - Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus on one subunit of IL-10 with little or no formation of monomeric IL-10. The method also provides a substantially homogenous population of mono-PEG-IL-10. | 2011-03-17 |
20110064691 | METHOD TO ENHANCE HEMATOPOIESIS - The present invention relates generally to the fields of immunology and molecular biology, and particularly to a method for treating hematopoietic disorders. The invention provides a method to treat a deficiency of one or more types of blood cells in a mammal, which includes administering an effective amount of TISF or of a compound that stimulates CD4+ cells like TISF does. In one embodiment, TISF that originates from a mammalian species is administered to a mammalian subject diagnosed as having a deficiency in one or more types of blood cells. | 2011-03-17 |
20110064692 | HUMAN BONE-FORMING CELLS IN THE TREATMENT OF CONDITIONS AND BONE DISEASES ASSOCIATED WITH IMMUNODEFICIENCY OR IMMUNOSUPPRESSION - The invention relates to novel therapeutic uses of isolated bone-forming cells, particularly in the treatment of diseases and conditions associated with immunodeficiency or immunosuppression. | 2011-03-17 |
20110064693 | Antiviral Drugs for Treatment of Arenavirus Infection - Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by the Arenavirus family such as Lassa fever, Argentine hemorrhagic fever, Bolivian hemorrhagic fever, and Venezuelan hemorrhagic fever. | 2011-03-17 |
20110064694 | ANTI-HEPATITIS C ACTIVITY OF MESO-TETRAKIS-PORPHYRIN ANALOGUES - The present invention relates to porphyrin analogues, their use in pharmaceutical compositions alone, or combination with other agents and in the treatment and/or prophylaxis of flaviviridae viral infections, especially hepatitis C viral infection, and secondary disease states and/or conditions associated with same. | 2011-03-17 |
20110064695 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2011-03-17 |
20110064696 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2011-03-17 |
20110064697 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2011-03-17 |
20110064698 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2011-03-17 |
20110064699 | REDUCING CONJUGATIVE PLASMIDS IN BACTERIA - The present invention provides methods and compositions to reduce prevalence of plasmids in microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions. Means are provided to reduce the copy numbers of antibiotic resistance genes, and to confer phage binding to cells lacking receptors for those phage. | 2011-03-17 |
20110064700 | NEURAL STEM CELLS - The invention provides compositions and methods for obtaining neural stem cells from post-natal subjects and their use in treating neurological disorders. | 2011-03-17 |
20110064701 | Pluripotent embryonic-like stem cells, compositions, methods and uses thereof - The present invention relates to pluripotent stem cells, particularly to pluripotent embryonic-like stem cells. The invention further relates to methods of purifying pluripotent embryonic-like stem cells and to compositions, cultures and clones thereof. The present invention also relates to a method of transplanting the pluripotent stem cells of the present invention in a mammalian host, such as human, comprising introducing the stem cells, into the host. The invention further relates to methods of in vivo administration of a protein or gene of interest comprising transfecting a pluripotent stem cell with a construct comprising DNA which encodes a protein of interest and then introducing the stem cell into the host where the protein or gene of interest is expressed. The present also relates to methods of producing mesodermal, endodermal or ectodermal lineage-committed cells by culturing or transplantation of the pluripotent stem cells of the present invention. | 2011-03-17 |
20110064702 | Methods and Kits for Enhancing Cell Survival, Stimulating Cell Proliferation, Treating Diabetic Patients, and/or Reinnervation - Methods for enhancing beta cell survival and/or for stimulating beta cell proliferation, comprise co-transplanting pancreatic islets, beta cells, and/or stem cells which can generate beta cells, with (i) neural crest stem cells (NCSCs), (ii) tetracycline-regulated gene expression system (Tet-System)-containing neural stem/progenitor cells (TetStock neural stem/progenitor cells), and/or (iii) pre-differentiated stem/progenitor neural cells. Methods for reinnervation in an organ or tissue transplant patient comprise co-transplanting with the organ or tissue (i) neural crest stem cells (NCSCs), (ii) tetracycline-regulated gene expression system (Tet-System)-containing neural stem/progenitor cells (TetStock neural stem/progenitor cells), and/or (iii) pre-differentiated stem/progenitor neural cells. Kits for conducting such methods employ at least one of (i) neural crest stem cells (NCSCs), (ii) tetracycline-regulated gene expression system (Tet-System)-containing neural stem/progenitor cells (TetStock neural stem/progenitor cells), and (iii) pre-differentiated stem/progenitor neural cells. | 2011-03-17 |
20110064703 | BONE SUBSTITUTE COMPOSITIONS, METHODS OF PREPARATION AND CLINICAL APPLICATIONS - The present invention relates to bone substitute compositions and methods of their preparation, and their use in a wide variety of clinical applications. The compositions include calcium phosphate, acidic calcium salt, basic calcium salt, sodium hydrogen phosphate and porogen. The compositions further include a mixing liquid. The compositions can optionally include biological signaling molecules and/or a growth compound. Further, the compositions can optionally include a plasticizer. | 2011-03-17 |
20110064704 | SHIP-DEFICIENCY TO INCREASE MEGAKARYOCYTE AND PLATELET PRODUCTION - A method of increasing megakaryocytes and platelet numbers in a patient comprising the step of inhibiting SHIP expression, including SHIP's enzymatic activity and signaling functions, whereby normal blood clotting is induced. | 2011-03-17 |
20110064705 | HEMANGIO COLONY FORMING CELLS AND NON-ENGRAFTING HEMANGIO CELLS - Methods of generating and expanding human hemangio-colony forming cells and non-engrafting hemangio cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells, non-engrafting hemangio cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Human non-engrafting hemangio cells are a novel progenitor cell population that is related to but distinct from the hemangioblast and human hemangio-colony forming cells. The invention also provides compositions, preparations, and solutions comprising hemangio-colony forming cells, non-engrafting hemangio cells or cells differentiated therefrom. The compositions, preparations, and solutions include cryopreserved preparations and substantially purified preparations, as well as mixed compositions formulated in combination with related hemangioblast progenitor cell types that can engraft into the bone marrow. | 2011-03-17 |
20110064707 | PROBIOTICS TO IMPROVE GUT MICROBIOTA - The use of probiotic bacteria in the manufacture of a medicament or therapeutic nutritional composition for promoting the development of an early bifidogenic intestinal microbiota in infants without siblings. | 2011-03-17 |
20110064708 | Methods And Compositions For The Dietary Management Of Autoimmune Disorders - The present invention describes the use of lactic acid bacteria, particularly lactic acid producing members of the genus | 2011-03-17 |
20110064709 | USE OF ECDI-FIXED CELL TOLERANCE AS A METHOD FOR PREVENTING ALLOGRAFT REJECTION - The present invention provides methods, systems, and compositions for inducing donor-specific tolerance. In particular, the present invention provides methods of administering ECDI-treated cells before, during, and/or after administration of donor transplant cells or a donor allograft in order to induce tolerance for the cells and/or allograft in a recipient. | 2011-03-17 |
20110064710 | NOVEL BACILLUS THURINGIENSIS ISOLATE - A novel bacterial strain of | 2011-03-17 |
20110064711 | COMPOSITIONS CONTAINING COENZYME Q-10 AND AN ANTIOXIDANT - The invention describes compositions of a reduced form of coenzyme Q-10 (CoQ10) or CoQ10 or both and an antioxidant that is an anthocyanin extract, a melanin or a compound having at least one thiol (—SH) group. | 2011-03-17 |
20110064712 | Dietary Supplement Compositions and Methods of Making and Using the Same - Dietary supplement compositions are disclosed. Methods of making and using dietary supplement compositions are also disclosed. | 2011-03-17 |
20110064714 | FACTOR VIIA-POLYSIALIC ACID CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE - The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma. | 2011-03-17 |
20110064715 | METHODS FOR DETERMINING OLIGOSACCHARIDE BINDING - The invention relates to methods for detecting and characterizing enzymatic modifications of oligosaccharides, such as heparan sulfate, and their interaction with binding partners, such as proteins, using an oligosaccharide-binding partner binding assay, such as a gel mobility shift assay. The instant invention relates to a rapid, convenient, sensitive and inexpensive method for identifying or studying oligosaccharide-binding partner interactions, identifying and characterizing structural features on oligosaccharides, identifying and characterizing binding partners, identifying agents capable of interfering with, enhancing, or facilitating the binding of an oligosaccharide to its binding partner, diagnosing conditions associated with altered oligosaccharide-binding partner binding, and generating oligosaccharide libraries and kits therefor. | 2011-03-17 |
20110064716 | MATERIALS AND METHODS FOR TREATING OR PREVENTING ORGANOPHOSPHATE EXPOSURE ASSOCIATED DAMAGE - A method of treating or preventing organophosphate exposure associated damage in a subject in need thereof is provided. The method comprising providing the subject with a therapeutically effective amount of AChE-R to thereby treat the organophosphate exposure associated damage in the subject. | 2011-03-17 |
20110064717 | Homing endonuclease genes and their targets - The invention provides pharmaceutical composition having as an active ingredient either a homing endonuclease (HE) capable of cleaving a non-native target nucleotide sequence in a genome or a nucleotide sequence encoding for a HE capable of cleaving a target site in a non-native genome. The invention also provides uses for such HEs, and methods of treatment utilizing such HEs. The HE may be, for example, any one of the HEs PI-SceI, POLB HE, PRP8 HE, or Nostoc species PCC7120 HE. | 2011-03-17 |
20110064718 | Pesticidal and Antiparasitic Compositions - This invention relates to pesticide and antiparasitic compositions for the control of pests, diseases and parasites attacking plants and animals. The compositions include, at least one chitinolytic agent or a chitinolytic activity-inducing agent, and sulfide or a sulfide-producing agent from microorganisms or chemical compounds, wherein the chitinolytic agent or the chitinolytic activity-inducing agent and sulfur or a sulfur-producing agent obtaining from microorganisms or chemical compounds are concurrently applied at a range significantly lower than any of the above-mentioned compounds, when they are individually to attain effective control. | 2011-03-17 |
20110064719 | HYDROPHOBIC INTERACTION CHROMATOGRAPHY PURIFICATION OF FACTOR VII POLYPEPTIDES - The invention described herein provides new methods of preparing purified Factor VII polypeptide drug substances in large quantities (industrial scale levels) that are associated with reduced content of product-related impurities (e.g., late eluting peaks) and/or that exhibit a relatively uniform glycosylation pattern. | 2011-03-17 |
20110064720 | Dietary Supplement Compositions and Methods of Making and Using the Same - Dietary supplement compositions are disclosed. Methods of making and using dietary supplement compositions are also disclosed. | 2011-03-17 |
20110064721 | CATHEPSIN-D NEUROPROTECTION - Provided herein are methods and compositions for promoting neuroprotection in a subject and for treating a neural disorder associated with protein aggregation comprising administering to the subject an agent that increases expression or activity of cathepsin-D. Also provided are methods of screening for agents that increase expression or activity of cathepsin-D and methods of screening for neuroprotective agents. | 2011-03-17 |
20110064722 | MODULATORS OF ALPHA-SYNUCLEIN TOXICITY - Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity. | 2011-03-17 |
20110064723 | Formulation for room temperature stabilization of a live attenuated bacterial vaccine - This invention provides methods and compositions for stabilizing proteins and vaccines in dried formulations. In particular, a cavitation method and compositions of preparing a dried vaccine are provided that stabilize the viability of live bacteria and live virus vaccines at room temperature. | 2011-03-17 |
20110064724 | Methods for Identifying Compounds for the Treatment of Type 1 Diabetes - The present invention provides methods of identifying candidate compounds for the treatment of type I diabetes comprising contacting pancreatic β cells with an amount of apolipoprotein CIII (“apoCIII”) effective to increase intracellular calcium concentration, in the presence of one or more test compounds, and identifying those test compounds that inhibit an apoCIII-induced increase in intracellular calcium concentration in the pancreatic β cells. The present invention also provides methods for treating patients with type I diabetes comprising administering to the patient an amount effective of an inhibitor of apoCIII to reduce apoCIII-induced increase in intracellular calcium concentration in pancreatic β cells. | 2011-03-17 |
20110064725 | HIGH AFFINITY, ANTI-HUMAN IGE ANTIBODIES - The invention relates to high affinity human monoclonal antibodies, particularly those directed against isotypic determinants of immunoglobulin E (IgE), as well as direct equivalents and derivatives of these antibodies. These antibodies bind to their respective target with an affinity at least 100 fold greater than the original parent antibody. These antibodies are useful for diagnostics, prophylaxis and treatment of disease. | 2011-03-17 |
20110064726 | ANTI IgE ANTIBODIES - The present invention relates to novel human antibodies specifically directed against human immunoglobulin E (anti-IgE). The present invention also relates to pharmaceutical compositions and methods for treating asthma, in particular allergic asthma, as well as other IgE-mediated disorders including allergic rhinitis and food allergies. | 2011-03-17 |
20110064727 | Immunoglobulin Variants Outside the Fc Region - The present invention relates to antibody variants outside the Fc region that alter binding affinity to one or more effector ligands, methods for their generation, and their therapeutic application. | 2011-03-17 |
20110064728 | IL-17 Homologous Polypeptides and Therapeutic Uses Thereof - The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases. | 2011-03-17 |
20110064729 | ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION - A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation. | 2011-03-17 |
20110064730 | METHOD OF MODULATING ANGIOGENESIS - A method for the identification of a nucleic acid molecule differentially expressed in an in vitro model of a biological system, comprising the steps of: (1) harvesting cells from the model system at predetermined time points; (2) obtaining total RNA from the cells harvested at each time point; (3) preparing cDNA from the total RNA from each time point to provide a plurality of pools of cDNA; (4) performing a suppression subtractive hybridization (SSH) on the cDNA pools from each time point sequentially so as to progressively amplify cDNAs derived from nucleic acid molecules differentially expressed from one time period to the next. | 2011-03-17 |
20110064731 | Use of IL-20 Antagonists for Treating Rheumatoid Arthritis and Osteoporosis - The invention features methods and compositions for preventing or treating rheumatoid arthritis and osteoporosis by administering an antagonist of IL-20. The IL-20 antagonist may be an anti-IL-20 antibody, such as mAB 7E, that is capable of binding human IL-20 and blocking IL-20 interaction with its receptors. | 2011-03-17 |
20110064732 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC USE IN CANCER PATIENTS - Disclosed herein are methods and compositions useful for identifying therapies likely to confer optimal clinical benefit for patients with cancer. | 2011-03-17 |
20110064733 | CA6 ANTIGEN-SPECIFIC CYTOTOXIC CONJUGATE AND METHODS OF USING THE SAME - Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CA6 glycotope. The present invention is also directed to humanized or resurfaced versions of DS6, an anti-CA6 murine monoclonal antibody, and epitope-binding fragments thereof. | 2011-03-17 |
20110064734 | PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE - Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components. | 2011-03-17 |
20110064735 | METHODS FOR TREATING LYMPHOMAS IN CERTAIN PATIENT POPULATIONS AND SCREENING PATIENTS FOR SAID THERAPY - Methods for predicting a response of a patient having a lymphoma to a therapy regimen of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione using prognostic factors of a patient's disease burden, absolute lymphocyte count or time since last rituximab therapy are disclosed. Specific methods of treating a lymphoma encompass the administration of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione to a patient who has one or more of the favorable profiles, alone or in combination with immunosuppressive agents such as rituximab. | 2011-03-17 |
20110064736 | TUMOR THERAPY WITH AN ANTIBODY FOR VASCULAR ENDOTHELIAL GROWTH FACTOR AND AN ANTIBODY FOR HUMAN EPITHELIAL GROWTH FACTOR RECEPTOR TYPE 2 - The present invention provides a method of treating a breast cancer disease in a patient who has failed prior treatment with an anti-VEGF antibody, comprising administering to the patient a therapeutically effective amount of an anti-HER2 antibody while continuing said anti-VEGF antibody therapy. The invention also provides corresponding pharmaceutical kits and pharmaceutical compositions. | 2011-03-17 |
20110064737 | ErbB ANTAGONISTS FOR PAIN THERAPY - The present application describes the use of ErbB antagonist, especially ErbB2 antibodies such as rhuMAb 2C4, for treating pain. | 2011-03-17 |
20110064738 | HUMAN ANTI-VEGF POLYCLONAL ANTIBODIES AND USES THEREOF - This invention relates to IVIG and fragments thereof and their use, specifically, provided herein are compositions and methods of inhibiting VEGF or VEGF receptor using polyclonal antibodies (pAb), or fragments thereof derived from human immunoglobulins. | 2011-03-17 |
20110064739 | MEDICAMENT, COMPOSITIONS, AND SUBSTANCES FOR TREATING AND IDENTIFYING ADENOCARCINOMA OF THE LUNG - The invention is based on the finding that in mammalian lungs c-myc acts as a molecular switch, specifically inducing an expression pattern in vivo, which results in prototypical mammalian adenocarcinoma of the lung and liver metastasis. A set of factors essential for the processes of tumorigenesis and tumor progression, i.e. cell cycle and apoptosis, cell growth, extracellular signaling, angiogenesis and invasion, is identified, whose expression is significantly changed. In particular, the expression pattern found uncovers the network of molecules leading to mammalian papillary adenocarcinomas of the lung. | 2011-03-17 |
20110064740 | ANTIGEN BINDING PROTEINS - The present invention relates to methods of treating diseases or disorders affecting the eye or optic nerve characterised by elevated β-amyloid levels or β-amyloid deposits, particularly age related macular degeneration and glaucoma type diseases and β-amyloid dependent cataract formation, with antigen binding proteins that bind β-amyloid peptide and in particular human β-amyloid peptide. | 2011-03-17 |
20110064741 | STABLE AMYLOID BETA MONOMERS AND OLIGOMERS - The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The alanines at positions 21 and 30, in wild type amyloid beta peptide amino acid sequence, are according to the invention replaced by cysteins, which results in an intra molecular disulphide bond. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides. | 2011-03-17 |
20110064742 | Somatostatin Receptor Antagonists and Glucose Control or Hypoglycemia - The present disclosure provides methods and uses for controlling tight blood glucose levels in a subject comprising administering an effective amount of a somatostatin inhibitor. The present disclosure provides methods and uses for treating or preventing hypoglycemia in a subject comprising administering an effective amount of a somatostatin inhibitor. | 2011-03-17 |
20110064743 | HUMAN ANTI-CANCER ANTIBODIES - The present invention provides novel human anti-cancer antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of cancer. | 2011-03-17 |
20110064744 | PREVENTION AND TREATMENT OF PAIN USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID - Methods for preventing or treating pain are provided, comprising administering to a subject, including a human subject, an antibody or antibody fragment that binds LPA. | 2011-03-17 |
20110064745 | Therapeutic Antibodies, Antibody Fragments And Antibody Conjugates - The present invention provides compositions, including pharmaceutical compositions, comprising an amount of an antibody, antibody fragment or antibody conjugate sufficient to treat Group A | 2011-03-17 |
20110064746 | TREATMENT OF DRUG-RELATED SIDE EFFECT AND TISSUE DAMAGE BY TARGETING THE CD24-HMGB1-SIGLEC10 AXIS - The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient. | 2011-03-17 |
20110064747 | METHODS FOR TREATMENT OF A SARCOMA USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) - Methods and formulations for treating a sarcoma in humans using an epimetabolic shifter, such as Coenzyme Q10, a building block of CoQ10, a derivative of CoQ10, an analog of CoQ10, a metabolite of CoQ10, or an intermediate of the coenzyme biosynthesis pathway, are described. Methods for assessing the efficacy of treatment of, diagnosing, and prognosing sarcoma are also provided. | 2011-03-17 |
20110064748 | PHARMACEUTICAL COMBINATION AND METHOD FOR TREATING TUMOR - Disclosed is a method for treating tumor in a mammalian subject, which comprises administering a combination of (a) an anti-tumor agent and (b) a fatty acid derivative represented by the formula (I): | 2011-03-17 |
20110064749 | COMPOSITIONS COMPRISING IMMUNOREACTIVE REAGENTS AND SAPONINS, AND METHODS OF USE THEREOF - The present invention relates to pharmaceutical compositions that are useful for the prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response, and methods of formulating the compositions. The compositions comprise an immunoreactive reagent (i.e., an antigen binding protein comprising an antigen binding region and a region or regions of an antibody that mediate antibody dependent immunological processes) and a saponin. The present invention also relates to methods of using the compositions of the invention for the prevention and/or treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response. | 2011-03-17 |
20110064750 | METHOD AND KIT FOR TREATING NICOTINE ADDICTION - Described are methods and kits related to treating nicotine addiction and increasing the likelihood of nicotine abstinence. Methods and kits for reestablishing nicotine abstinence after a relapse to nicotine use are also described. | 2011-03-17 |
20110064751 | TARGETED IMMUNOCONJUGATES - The present invention relates to immunoconjugates. In particular embodiments, the present invention relates to immunoconjugates comprising at least one single-chain effector moiety and two or more antigen binding moieties. In addition, the present invention relates to nucleic acid molecules encoding such immunoconjugates, vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease. | 2011-03-17 |
20110064752 | EXTRACELLULAR TARGETED DRUG CONJUGATES - The present invention relates to, inter alia, extracellular drug conjugates (EDC) in which an antibody or other targeting agent (e.g. a targeting moiety) is linked to a drug through a linker (e.g. a non-cleavable linker). These conjugates are useful in the treatment of disease and/or as a tool in the evaluation of biological systems. | 2011-03-17 |
20110064753 | DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE - Drug-Linker-Ligand Conjugates are disclosed in which a Drug is linked to a Ligand via a peptide-based Linker unit. In one embodiment, the Ligand is an Antibody. Drug-Linker compounds and Drug compounds are also disclosed. Methods for treating cancer, an autoimmune disease or an infectious disease using the compounds and compositions of the invention are also disclosed. | 2011-03-17 |
20110064754 | Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines - The present invention concerns methods and compositions for subunit-based vaccines for inducing immunity against poxvirus infections, such as smallpox. Preferred embodiments concern immunoconjugates comprising one or more subunit antigenic peptides attached to an antibody or fragment thereof that targets antigen-producing cells (APCs). More preferably, the antibody binds to HLA-DR and the antigenic peptide is from an immunomodulating factor, such as the viral IL-18 binding protein (vIL18BP). However, mixtures of antigenic peptides from different viral proteins may also be used. The vaccine is capable of inducing immunity against poxvirus without risk of disseminated infection in immunocompromised hosts or transmission to susceptible contacts. | 2011-03-17 |
20110064755 | METHODS FOR PRODUCING BLOCK COPOLYMER/AMPHIPHILIC PARTICLES - The invention relates to a method for manufacturing cell delivery particles, pharmaceutical component-particle dispersions, compositions comprising cell delivery particles and pharmaceutical compositions comprising pharmaceutical component-particle dispersions. The method comprises homogenization of mixtures comprising amphiphilic components and a block copolymer to form stable particles. The invention is also directed to cell delivery particles and pharmaceutical component-particle dispersions produced by the claimed methods and compositions comprising same. In certain embodiments, the cell delivery particles may further comprise co-lipids. The invention further relates to methods of generating an immune response, treating or preventing a disease or condition, or delivering a biologically active molecule to cells in vitro comprising administration of the pharmaceutical compositions described herein. | 2011-03-17 |
20110064756 | NOVEL SEQUENCES OF BRACHYSPIRA, IMMUNOGENIC COMPOUNDS, METHODS FOR PREPARATION AND USE THEREOF - Novel polynucleotide and amino acids of | 2011-03-17 |
20110064757 | NUCLEIC ACID MOLECULES AND POLYPEPTIDES FOR IMMUNE MODULATION - The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds. | 2011-03-17 |
20110064758 | INFECTIOUS CLONES OF TORQUE TENO VIRUS - The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus (“TTV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include vaccines that provide TTV ORF1 protein, or peptide fragments thereof, as antigen. | 2011-03-17 |
20110064759 | Method for the Identification of Extracellular Domains of Epstein Barr Virus (EBV) Tumor-Associated Latent Membrane Proteins and for the Selection of Antibody Reagents Reactive Therewith - Described are a method for the identification of extracellular epitopes of Epstein Barr virus (EBV) encoded membrane proteins, expressed on the cuter cell surface of EBV-transformed mammalian cells, methods for the selection and preparation of antibody reagents specific for the said epitopes, as well as peptides, including extracellular domains of Epstein Barr Virus encoded tumour cell associated membrane proteins, the use of said peptide for immunization and therapeutic vaccination to induce antibodies and T-cells reactive with said domains, the use of said antibody reagents for the production of targeting cells, tumour cell purging and as diagnostic for and medicament against EBV-mediated malignant cell growth. | 2011-03-17 |
20110064760 | POLYPEPTIDES COMPRISING EPITOPES OF HIV GP41 AND METHODS OF USE - An isolated polypeptide that has an amino acid sequence that is substantially homologous to consecutive amino acids of a c-terminal portion of the membrane proximal external region (MPER) of gp41 includes an immunogenic epitope reactive with at least one anti-HIV antibody. | 2011-03-17 |
20110064761 | NOVEL SEQUENCES OF BRACHYSPIRA, IMMUNOGENIC COMPOSITIONS, METHODS FOR PREPARATION AND USE THEREOF - Novel polynucleotide and amino acids of | 2011-03-17 |
20110064762 | PROTEIN A COMPOSITIONS AND METHODS OF USE - Methods and compositions for modulating an immune response in a subject are provided. Methods include administering to the subject a composition comprising an effective amount of a lymphocyte differentiation factor, e.g., protein A (PA), sufficient to modulate the immune response. Compositions include a lymphocyte differentiation factor, e.g., protein A (PA), in an amount less than 1 μg. | 2011-03-17 |
20110064763 | LENTIVIRAL VECTORS PSEUDOTYPED WITH A SINDBIS VIRUS ENVELOPE GLYCOPROTEIN - Lentiviral vector particles comprising a Sindbis virus E2 glycoprotein variant and a lentiviral vector genome comprising a sequence of interest are provided. A lentiviral vector particle comprising: (a) an envelope comprising a Sindbis virus E2 glycoprotein variant; and (b) a lentiviral vector genome comprising a sequence of interest; wherein the E2 glycoprotein variant facilitates infection of dendritic cells by the lentiviral vector particle, and wherein the E2 glycoprotein variant has reduced binding to heparan sulfate compared to a reference sequence (HR strain). | 2011-03-17 |
20110064764 | Attenuated Live Triple G Protein Recombinant Rabies Virus Vaccine for Pre- and Post-Exposure Prophylaxis of Rabies - The invention provides a recombinant rabies viruses comprising three copies of a mutated G gene wherein each G gene encodes a rabies virus glycoprotein having the amino acid 194 mutated to a serine and the amino acid 333 is mutated to a glutamic acid. The recombinant rabies virus is nonpathogenic in immunodeficient mammals and can be used in a vaccine to induce an immune response protect mammals from infection by rabies virus as well as clear a pre-existing rabies virus infection from neural tissues. | 2011-03-17 |
20110064765 | PCV-2 VACCINE - The present invention relates to a vaccine against porcine circovirus type 2 (PCV-)2 and a method for the manufacture of such a vaccine, for protecting piglets against PCV-2 infection. It has been found that a vaccine comprising at least 20 microgram/dose of ORF-2 protein of porcine circovirus type 2 (PCV-2 is capable of eliciting a protective immune response against PCV-2 (and thus against PMWS) even when they have a relatively high titer of MDA against PCV-2. | 2011-03-17 |
20110064766 | Attenuated Vaccine Against Fish Pathogen Francisella Sp. - An attenuated bacteria has been made by an insertion mutation in the iglC gene of | 2011-03-17 |
20110064767 | CDNA CONSTRUCT OF SALMONIDAE ALPHAVIRUS - The invention concerns recombinant DNA's comprising c NDA of genomic RNA of a Salmonidae alphavirus preceded by a spacer sequence, under the control of a suitable promoter. Said recombinant DNA's are useful for obtaining expression vectors, producing recombinant Salmonidae alphavirus, and for obtaining vaccines. | 2011-03-17 |
20110064768 | Immunogenic Compositions - An immunogenic composition comprising a viral vector, said vector comprising a nucleic acid sequence encoding a C4bp domain or variant or fragment thereof and a nucleic acid sequence encoding an antigen of interest. | 2011-03-17 |
20110064769 | VV PROMOTER-DRIVEN OVEREXPRESSION OF RECOMBINANT ANTIGENS - The present invention is directed to the use of a pharmaceutical composition comprising a vaccinia virus (VV) based vector construct under the control of a strong VV specific promoter. The present invention is in particular directed to the use of this pharmaceutical composition for the treatment of infectious diseases, chronic inflammatory or degenerative diseases, and cancer and for evoking an immune response against subdominant and/or cryptic epitopes. | 2011-03-17 |
20110064770 | Immunization of an Individual Against Carcinomas and the Preliminary Stages Thereof - The present invention relates to a pharmaceutical composition, comprising a cell cycle regulatory protein and/or an expressible nucleic acid coding for this in an amount suitable for immunization of an individual against carcinomas and the preliminary stages thereof and common auxiliary agents and/or to the use of a cell cycle regulatory protein and/or an expressible nucleic acid coding for this to immunize an individual against carcinomas and the preliminary stages thereof. | 2011-03-17 |
20110064771 | PLANT EXTRACTS AND USES THEREOF - Plant extracts obtainable by extracting various plant materials with an alkaline agent, methods for preparing such extracts, compositions comprising such extracts, and methods for using the extracts or compositions thereof are described. | 2011-03-17 |
20110064772 | VIRAL ADJUVANTS - The present invention provides viral adjuvants for enhancing an immune response to an immunogen. In particular embodiments, the viral adjuvant is an alphavirus adjuvant or a Venezuelan Equine Encephalitis viral adjuvant. Also provided are compositions comprising the viral adjuvant and an immunogen, and pharmaceutical formulations comprising the viral adjuvant or compositions of the invention in a pharmaceutically acceptable carrier. Further provided are methods of producing an immune response against an immunogen in a subject comprising administering the immunogen and a viral adjuvant of the invention to the subject. | 2011-03-17 |
20110064773 | PHARMACEUTICAL COMPOSITIONS COMPRISING A THYROID HORMON AND THEIR THERAPEUTIC USE - The present invention relates to a pharmaceutical composition comprising, as active substance, at least one hormone chosen among 3′,5′,3-triiodothyronine (rT3), a rT3 derived hormone, or a precursor of rT3, such as T4 in association with a molecule susceptible to promote the formation of rT3, in association with a pharmaceutically acceptable vehicle. | 2011-03-17 |
20110064774 | BULKING AGENT - The invention relates to bulking agents and apparatus and methods for using the disclosed bulking agents. The bulking agents can be used to treat such conditions as urinary and fecal incontinence, gastro-esophageal reflux, aneurismal blockages, and cosmetic deformities. The invention also relates to an injection method that reduces the injection pressure required to place the bulking agents. | 2011-03-17 |